|
Chris Ehrlich is a Partner with InterWest Partners, a leading diversified venture capital firm. As a member of the Life Sciences team, Mr. Ehrlich’s focus is investing in and building new businesses around entrepreneurs with novel technologies. He currently serves on the boards of BioMimetic Pharmaceuticals, Carbylan BioSurgery, Inc., KAI Pharmaceuticals, QuatRx Pharmaceuticals, TransOral Pharmaceuticals, Inc. and Xenon Pharmaceuticals. He is also an observer on the board of Applied Genetic Technologies Corporation and a founder of AlgoRx Pharmaceuticals, which recently merged with Corgentech (to form Anesiva Pharmaceuticals. Prior to joining InterWest in 2000, Ehrlich was Director, Licensing & Business Development at Purdue Pharma, a private pharmaceutical firm based in Stamford, CT. In this position, he was responsible for developing a biologic oncology franchise, including inlicensing key intellectual properties, establishing and managing collaborations with biotechnology companies and participating in the commercial operations of Purdue BioPharma, a biotechnology company located in Princeton, NJ. Prior to joining Purdue, Ehrlich worked in business development at Genentech, Inc., in venture capital at The U.S. Russia Investment Fund, and in biotechnology strategy development at LEK Consulting. Ehrlich earned his Bachelor’s degree from Dartmouth College, cum laude and an MBA from the J.L. Kellogg Graduate School of Management where he serves as an instructor and advisor to the Biotech Program. | 